Eli Lilly slashes Zepbound to £227 ($299) monthly for US cash payers, but just £31 ($41) in India – though £241 ($319) in Japan.

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Bariatric doctors who regularly prescribe GLP-1s share how long the worst Ozempic side effects last, and the best ways to ...

Calls have been more popular than usual in the options pits. LLY's 50-day call/put volume ratio of 2.23 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Eli Lilly has cut cash prices for its weight-loss drug Zepbound on LillyDirect, lowering monthly costs to $299–$449. The move ...

Eli Lilly and Company (LLY) is a global pharmaceutical leader focused on discovering, developing, and commercializing ...

With no evidence base to draw upon, clinicians are sharing strategies to help patients stop taking the new weight-loss drugs ...

New guidelines from the World Health Organization (WHO) recommend using GLP-1 medications to help manage obesity along with a healthy diet and regular exercise.

The cross-asset backdrop is classic late-cycle: softer yields, a weaker dollar and bifurcated risk appetite. The U.S. Dollar Index (DXY) dropped roughly 0.6% to around 98.24, its lowest reading since ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...